Nutriband Stock Price, News & Analysis

Nutriband Inc. (NTRBW) is a manufacturing-sector company primarily engaged in the development of a portfolio of prescription transdermal pharmaceutical products. The company focuses on transdermal systems that use patches to deliver drugs through the skin. According to Nutriband, its lead product under development is an abuse-deterrent fentanyl transdermal system that incorporates the company’s proprietary AVERSA™ abuse-deterrent transdermal technology.

Nutriband’s AVERSA technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulant drugs. The company states that this technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while maintaining access for patients who need these medications for the management of severe, chronic pain. Nutriband trades its common stock under the symbol NTRB and its warrants under the symbol NTRBW on The Nasdaq Stock Market LLC.

Business focus and AVERSA™ technology

Nutriband describes itself as being primarily engaged in the development of transdermal pharmaceutical products. Its lead product, often referenced as AVERSA™ FENTANYL, combines Nutriband’s AVERSA abuse-deterrent technology with an FDA-approved fentanyl patch developed by its partner Kindeva Drug Delivery. The proposed indication for this product is the management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock, long-term opioid treatment where alternative options are inadequate.

The AVERSA technology uses a proprietary aversive agent coating intended to deter oral abuse and reduce accidental exposure. Nutriband reports that AVERSA can be incorporated into any transdermal patch for drugs with abuse potential, with the goal of deterring abuse and misuse and reducing the risk of accidental exposure, including in pediatric settings. The company highlights that its AVERSA technology is protected by a broad intellectual property portfolio, with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, and patents issued in a total of 46 countries.

Lead product: AVERSA™ FENTANYL

AVERSA FENTANYL is described by Nutriband as an abuse-deterrent fentanyl transdermal system and the company’s lead product under development. Nutriband states that this product has the potential to be the world’s first abuse-deterrent opioid patch designed to deter abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. The company has reported that AVERSA FENTANYL has the potential to reach peak annual U.S. sales within a specified range, based on an external market analysis report, and notes that the unmet medical need for adequate pain management is a global issue.

Development of AVERSA FENTANYL has included work on commercial manufacturing process scale-up and regulatory interactions. Nutriband has reported completion of commercial manufacturing process scale-up for AVERSA FENTANYL and has held a virtual face-to-face meeting with the U.S. Food and Drug Administration (FDA) to obtain feedback on Chemistry, Manufacturing, and Controls (CMC) plans from Investigational New Drug (IND) submission through a 505(b)(2) New Drug Application (NDA) and eventual commercialization. The FDA confirmed the 505(b)(2) NDA regulatory pathway and provided guidance on the reference listed drug, bridging strategy, registration batch planning, manufacturing process validation, product specifications, stability testing, and in vitro studies to characterize abuse-deterrent properties.

Intellectual property and patent activity

Nutriband emphasizes intellectual property as a core asset supporting its AVERSA platform. The company has reported receiving a Notice of Allowance for a U.S. patent covering its transdermal abuse-deterrent technology and the issuance of a U.S. patent entitled “Abuse and Misuse Deterrent Transdermal Systems,” which further strengthens its patent protection and extends the duration of its IP coverage. Nutriband has also filed a provisional patent application with the U.S. Patent and Trademark Office to enhance AVERSA’s abuse-deterrent properties through improved aversive formulations and coating application methods.

According to Nutriband, if the provisional application is converted into a non-provisional application and results in a granted patent, it could significantly extend patent protection for products that utilize AVERSA technology, as U.S. patents generally have a statutory term measured from the non-provisional filing date. The company consistently notes that its AVERSA technology is covered by a broad international portfolio with patents issued in multiple major markets.

Partnerships and collaborations

Nutriband has disclosed several collaborations related to its AVERSA platform and lead product. The company is partnering with Kindeva Drug Delivery, described as a contract development and manufacturing organization (CDMO), to develop AVERSA FENTANYL by combining AVERSA technology with Kindeva’s FDA-approved fentanyl patch. Nutriband and Kindeva have revised their commercial development and clinical supply agreement to formalize an exclusive product development partnership and a long-term commitment based on shared development costs in exchange for milestone payments.

Through its 4P Therapeutics subsidiary, Nutriband has also signed an agreement with Brand Institute, Inc. to develop the worldwide commercial brand name and visual identity for its lead abuse-deterrent fentanyl transdermal system. Brand Institute and its regulatory subsidiary Drug Safety Institute will support name development and regulatory review to help ensure that the eventual proprietary name is distinguishable and aligned with regulatory naming guidance.

In addition, Nutriband has signed a non-binding Letter of Intent with the Qvanta Group of Companies to explore potential collaboration areas related to advanced technology solutions, including secure AI and analytics platforms for regulated pharmaceutical data, cybersecurity and data-integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation capabilities. The company notes that this LOI is non-binding and does not create a definitive commercial relationship.

Corporate actions and capital structure

Nutriband is incorporated in Nevada and identified as an emerging growth company in its SEC filings. Its securities registered under Section 12(b) of the Securities Exchange Act include common stock trading under the symbol NTRB and warrants trading under the symbol NTRBW on The Nasdaq Stock Market LLC.

The company has reported several capital-related events. In an 8-K filing, Nutriband disclosed that from February 1 through July 31 of a specified year, stock options and various warrants, including public warrants trading as NTRBW and privately held warrants, were exercised for shares of common stock for stated total exercise prices. In another 8-K, Nutriband described a stock dividend of Series A Convertible Preferred Stock to shareholders of record on a specified date, on the basis of one share of Series A Preferred Stock for each four shares of common stock held, with fractional shares rounded down.

The Board of Directors approved an amendment to the Articles of Incorporation to authorize a series of non-voting Series A Convertible Preferred Stock and later increased the authorized number of Series A Preferred shares through a Certificate of Correction. The terms of the Series A Preferred Stock provide that, following FDA approval for commercial sale of the company’s transdermal pharmaceutical products based on AVERSA abuse-deterrent technology, each share of Series A Preferred Stock will be convertible at the option of the holder into one share of common stock. Holders who do not convert their shares are eligible for dividends as declared by the Board of Directors.

Strategic transactions and index inclusion

Nutriband has announced an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for a stated cash consideration to EarthVision Bio, while retaining a 10% shareholding in the acquiring entity. The company has indicated that it plans to use the proceeds from this sale toward continued development of AVERSA FENTANYL. Nutriband has also reported that it was added to several Russell indexes as part of a Russell index reconstitution, including the Russell Microcap and Russell 3000E-related indexes.

Warrants (NTRBW) and investor considerations

The NTRBW symbol represents Nutriband’s warrants listed on Nasdaq. These warrants are referenced in SEC filings as public warrants to purchase shares of the company’s common stock. Nutriband has noted that warrants issued in connection with its initial public offering have an expiration date and has discussed the potential impact of these warrants on stock volatility. Investors analyzing NTRBW may consider the relationship between the warrants and the underlying common stock NTRB, as well as the company’s broader capital structure, including Series A Preferred Stock that is convertible upon FDA approval of AVERSA-based products.

Company communications and events

Nutriband regularly issues press releases describing its development progress, regulatory interactions, patent activity, and corporate actions. The company has highlighted shareholder-focused measures such as a preferred stock dividend and has provided commentary on strategic priorities, including advancing AVERSA FENTANYL toward commercialization and emphasizing shareholder value. Nutriband has also participated in investor conferences, such as events organized by Noble Capital Markets and the MicroCap Rodeo Conference, where its management presents operational highlights, growth initiatives, and the strategic direction of the AVERSA platform.

FAQs about Nutriband Inc. (NTRBW)

• What does Nutriband Inc. do?
  

  Nutriband Inc. is primarily engaged in the development of a portfolio of prescription transdermal pharmaceutical products. Its lead product under development is an abuse-deterrent fentanyl transdermal system that incorporates the company’s AVERSA abuse-deterrent technology.

• What is AVERSA™ abuse-deterrent transdermal technology?
  

  AVERSA is Nutriband’s proprietary abuse-deterrent transdermal technology that incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential, including opioids and stimulant drugs. The company states that this technology can improve the safety profile of transdermal drugs susceptible to abuse.

• What is AVERSA™ FENTANYL?
  

  AVERSA FENTANYL is Nutriband’s lead product under development, described as an abuse-deterrent fentanyl transdermal system. It combines AVERSA technology with an FDA-approved fentanyl patch from Kindeva Drug Delivery and is intended for opioid-tolerant patients requiring long-term, around-the-clock pain management.

• How is Nutriband’s AVERSA technology protected?
  

  Nutriband reports that its AVERSA abuse-deterrent transdermal technology is protected by a broad international intellectual property portfolio, with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia, and patents issued in a total of 46 countries.

• What are NTRB and NTRBW on Nasdaq?
  

  NTRB is the trading symbol for Nutriband Inc.’s common stock on The Nasdaq Stock Market LLC. NTRBW is the trading symbol for Nutriband’s publicly traded warrants, which are exercisable for shares of the company’s common stock under the terms described in its offering documents and SEC filings.

• How does the Series A Preferred Stock work?
  

  According to Nutriband’s 8-K filing, Series A Convertible Preferred Stock was authorized and issued as a stock dividend to shareholders of record on a specified date. Following FDA approval for commercial sale of the company’s transdermal pharmaceutical products based on AVERSA technology, each share of Series A Preferred Stock will be convertible, at the holder’s option, into one share of common stock. Holders who do not convert may be eligible for dividends as declared by the Board of Directors.

• What capital events involving warrants and options has Nutriband reported?
  

  In an 8-K filing, Nutriband disclosed that, over a defined period, stock options, public warrants trading as NTRBW, and privately held warrants were exercised for shares of common stock, with specified total exercise prices. The company has also discussed the expiration date of warrants issued in connection with its initial public offering.

• What partnerships support Nutriband’s product development?
  

  Nutriband is partnering with Kindeva Drug Delivery to develop AVERSA FENTANYL by combining AVERSA technology with Kindeva’s FDA-approved fentanyl patch. Through its 4P Therapeutics subsidiary, Nutriband has engaged Brand Institute to develop the commercial brand name and visual identity for its lead product. The company has also signed a non-binding Letter of Intent with the Qvanta Group of Companies to explore advanced technology solutions that may support its research and product development.

• How does Nutriband describe the medical need addressed by AVERSA FENTANYL?
  

  Nutriband notes that FDA-approved transdermal fentanyl patches are used for opioid-tolerant patients with severe chronic pain requiring long-term, around-the-clock opioid treatment when other options are inadequate. The company highlights ongoing issues with transdermal fentanyl patch abuse and accidental exposures and positions AVERSA FENTANYL as a potential abuse-deterrent option to address these concerns.

• Is Nutriband still an emerging growth company?
  

  In its 8-K filings, Nutriband identifies itself as an emerging growth company under applicable Securities Act and Exchange Act definitions and indicates whether it has elected certain transition provisions related to new or revised financial accounting standards.